Annual reportSep 2026
Sep 2026 · Intimation - Regulation 36(1)(B) Of The SEBI Listing Regulations 11 Sep - Krsnaa Diagnostics dispatched FY2025-26 annual report; 16th AGM scheduled for September 28, 2026.
Source: Bse
Krsnaa Diagnostics Limited (KRSNAA)
Small CapPharma stocks · Small cap · NSE
Krsnaa Diagnostics Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
₹512.8
+0.00 · +0.00%
Market cap ₹1,814 Cr
Data qualityFresh enough for analysisQuote updated 21 Oct, 12:17 pm ISTDetails
Quote21 Oct, 12:17 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 11:23 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Oct 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
50Neutralfull bear SMA stack · SMA20 -2.0% / mo · MACD − · near 52W low · sector +4.3pp vs Nifty 500 (3M)
Stock trend: 18
Sector RS: 99
Sector 3M: -1.6% vs Nifty 500 -5.9%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
KRSNAAD candles · FIT view-13.1%TODAY · PROVISIONALLatest price ₹512.80 on 2026-10-21
Today's candle is provisional from the latest intraday quote; completed-candle scans remain unchanged.
Bar
+0.4%
RSI
35
MACD hist
-3.11
52W pos
3%
2026-10-21O ₹511.00H ₹515.45L ₹504.00C ₹512.80Vol 29,479 shIntraday candle
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
KRSNAANifty PharmaNifty 500
- KRSNAA
- -6.2%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -0.6 pp
Chart stats
19 Oct 2026- From 52W high
- -39.5%
- 52W range position
- 1%
- ATR (14)
- 3.4%
- Volume vs 20D
- 1.13x
- Avg traded value
- ₹3.3 Cr
- 20D price channel
- ₹510.6 - ₹573.9
₹848.1
₹510.6 - ₹848.1
₹17.2
Latest completed session
20-session average
28.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · OVERVALUED30
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +22.3% · PAT -19.1% YoY
Technical
Neutral50
Price trend and sector-relative-strength timing.
Valuation
Legacy model-276.8%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence67
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 2/100PAT -19% YoY · margin compression · Rev +22% YoY · +22% QoQ
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹236 Cr | +22.3% | +22.3% |
| EBITDA | ₹58 Cr | +13.7% | +5.5% |
| Operating margin | 25.0% | -200 bps | -300 bps |
| PAT | ₹17 Cr | -19.1% | -59.5% |
| PAT margin | 7.2% | -368 bps | -1456 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 18.60
- P/B
- 1.85
- EV/EBITDA
- 7.45
- Market Cap
- 1814.00Cr
Profitability
- ROE
- 10.90%
- ROCE
- 12.70%
- ROA
- 5.33%
- Dividend Y
- 0.36%
Growth (CAGR)
- Revenue 5Y
- -7.00%
- EPS 5Y
- -7.00%
- Revenue 3Y
- 17.00%
- EPS 3Y
- 18.00%
Balance Sheet
- Debt/Equity
- 0.54
- Interest Coverage
- 5.07×
- Altman Z
- 3.08
- Book Value
- 302.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 143.00 Cr
- EPS TTM
- 30.04
Shareholding
- Promoter Hold
- 27.11%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 16%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 236+22.3% vs prev
Net Profit
₹ CrLatest: 17.0-59.5% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 35.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~2.4% over last month) — short-term momentum negative.
- RSI(14) at 35 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
25
RS percentile
Stage 4 Downtrend
1M return
-5.2%
3M return
-6.2%
6M return
-15.2%
1Y return
-35.5%
RS 1D
-2
RS 20D
0
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 8.1% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.7%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 68.72-2.86%
RS vs Nifty 50069
Valuation & peers
U-Score 30 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 30 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation10/30
Growth3/25
Quality3/20
Balance Sheet7/15
Cash Flow1/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
30
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
30/100 · legacy band OVERVALUED
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 7/15 to the score.
- Valuation contributes 10/30 to the score.
Main drags
- Fair-value margin of safety is negative at -276.8%.
- Cash flow is weaker at 1/10; verify the latest quarterly trend.
- Growth is weaker at 3/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
18.6
PB
1.9
EV/EBITDA
7.5
ROE
10.9%
ROCE
12.7%
FCF Yield
—
Debt/Equity
0.5
MoS
-276.8%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
30
Previous: 30
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-276.8%
Previous: -276.8%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
30
30
30
30
30
30
30
30
30
30
30
30
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹451.8
-13.5% MoS
Growth-justified P/E
4.5
Growth-justified Value
₹136.08
-276.8% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SURAKSHA
Small
Suraksha Diagnostic Limited
Healthcare Services
match 170
52
48.3
14.2%
+4%
FAIR VALUE
SAKAR
Small
Sakar Healthcare Limited
Healthcare Services
match 165
38
62.1
10.0%
-26%
WATCHLIST
TTKHLTCARE
Small
TTK Healthcare Limited
Healthcare Services
match 165
46
18.6
6.3%
+56%
FAIR VALUE
INDOCO
Small
Indoco Remedies Limited
Healthcare Services
match 164
18
—
-9.4%
-10580%
OVERVALUED
SYNCOMF
Small
Syncom Formulations (India) Limited
Healthcare Services
match 163
66
25.4
17.6%
+48%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Krsnaa Diagnostics Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
67Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 52nd percentile of the scored universe and 39th percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
92 docs text-extracted · 38 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
52nd percentile
overall median 67 · Pharma: 39th pctile, median 70 · Small: 56th pctile, median 66
Evidence depth
Financial-only
92 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
75
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸OPM spread across recent quarters is 4%.
Trust risks
- ▸Only 1 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Krsnaa Diagnostics Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement Under Regulation 30 (6) Of The SEBI (LODR) Regulations, 2015 28 Sep - Board approved sale of diagnostic equipment for up to ₹120 crore to optimise capital efficiency.
Source: Bse
Announcement
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 9 Sep - CIT(A), Pune passed seven income-tax orders for AY2017-18 to AY2023-24; disputed demand totals ₹62.69 crore.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Sep - Newspaper Publication for the Notice convening 16th Annual General Meeting of the Company
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Announcement
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - General Updates 20 Aug - Krsnaa Diagnostics plans preferential issue of 16.21 lakh warrants worth ₹91.75 crore to two investors.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Jun - Newspaper Publication for issue of Postal Ballot Notice
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 25 May - Krsnaa Diagnostics reported FY2026 revenue of ₹7,728 million, PAT up 31% to ₹1,014 million, and ₹2 final dividend.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
Annual report
Business Responsibility and Sustainability Reporting (BRSR) 5 Sep - Krsnaa Diagnostics submitted BRSR for FY 2025-26 with annual report and 16th AGM notice.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.